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Abstract
Local anaesthetics are commonly used drugs in clinical anaesthesia. The knowledge 
of their pharmacology is paramount for safe and optimal use of this group of drugs. 
This chapter consists of two sections. The first section will address the chemical and 
physical properties, pharmacokinetics and pharmacodynamics of the local anaesthet‐
ics. In the second section, examples of the commonly used doses and additives used 
for various peripheral and regional anaesthetics will be discussed. We will also address 
the treatment of toxicity as a result of inadvertent intravascular injection of the local 
anaesthetics.
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Summary points
1. Local anaesthetics block the transmission of pain from the nerve endings into the central 
nervous system. Chemically, they are classified as esters and amides depending on the 
intermediate chain between the lipophilic aromatic ring and the hydrophilic amine group.
2. The primary mode of action is blockade of the fast voltage‐gated sodium channels. To 
achieve this effect, the unionised fraction of the drug crosses the lipid bilayer of the axo‐
plasm and blocks the channel intracellularly.
3. The duration and density of the block depend on both the volume and concentration of 
the agent used.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
4. Factors that influence the efficacy of local anaesthetics are the pH, pKa, lipid solubility, pro‐
tein binding and the length of the intermediate chain. Efficacy can be augmented by use of ad‐
juncts such as adrenaline, opioids, alpha 2‐adrenergic agonists (clonidine) and alkalinisation.
5. Toxicity is related to the site of injection, the vascularity of the site and the injected dose. 
The use of vasoconstrictors may reduce toxicity due to reduction in systemic absorption.
6. From the local anaesthetics in clinical use, racemic bupivacaine has the highest affinity for 
the sodium channels and is the most difficult to manage in the event of systemic toxicity.
1. The neuron and pharmacology of local anaesthetics
1.1. Introduction
Local anaesthetics are drugs that block conduction of electrical impulses in excitable tissues. These 
tissues include the nerve cells and myocytes (both cardiac and skeletal muscles). Analgesia and 
anaesthesia occur as a result of the blockage of electrical impulses. Other local anaesthetics like 
lidocaine also possess Class I antiarrhythmic properties. Before a detailed venture into the physi‐
cal‐chemical properties and mechanism of action of this class of drugs, a brief overview of the 
nerve anatomy is discussed. This will aid in the overall understanding of how these agents work 
and how their efficacy and safety can be improved by the use of appropriate doses and adjuncts.
1.2. Nerve anatomy
Neurons are the primary cells in the nervous system. The nervous system is made up of the 
central and peripheral nervous system. It can also be looked at in terms of parasympathetic 
and sympathetic nervous system. A group of neurons bundled together make up peripheral 
nerves. The basic structure of a neuron is illustrated in Figure 1.
Figure 1. Structure of a neuron. Source: http://www.vce.bioninja.com.au/aos‐2‐detecting‐and‐respond/coordination‐‐
regulation/nervous‐system.html. Used with permission 05/11/2016.
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Peripheral nerves contain both afferent and efferent fibres, which are bundled into one or 
more fascicles as illustrated in Figure 2. Individual nerve fibres within the fascicle are sur‐
rounded by a layer of loose connective tissue called the endoneurium. The endoneurium 
houses the glial cells, fibroblasts and blood vessel capillaries, all of which are integral to 
the function of the nerve fibre. The fascicle is in turn surrounded by a dense layer of collag‐
enous connective tissue called the perineurium. A cylindrical sheath called the epineurium 
forms the outermost layer of a peripheral nerve. The main function of these layers is to pro‐
tect the nerve fibres and also act as barriers to agents acting on the nerves including local 
anaesthetics.
1.3. Electrophysiology of nerve conduction
The resting membrane potential of a nerve cell is in the range of −60 to −70 mV. At rest, 
neurons are more permeable to potassium ions due to the presence of potassium leak chan‐
nels. This explains why the resting neuronal membrane potential is closer to the equilib‐
rium potential of potassium of −80 mV. The ionic disequilibria acts as the energy needed 
for propagation of action potentials on the cell surface [1]. The intracellular milieu of the 
nerve cell is negatively charged relative to the extracellular. Upon excitation of the nerve 
fibres, the electrical impulse propagates along the axon as a result of changes occurring in 
the adjacent membrane alternating from negative to positive values of about +50 mV due 
to rapid influx of sodium ions. At an electrical potential of +50 mV, there is rapid efflux 
Figure 2. Peripheral nerve. Source: https://www.studyblue.com/#flashcard/review/8819508.
Pharmacology of Local Anaesthetics and Commonly Used Recipes in Clinical Practice
http://dx.doi.org/10.5772/67048
5
of potassium ions in an attempt to maintain electrical neutrality of the cell. To restore the 
resting membrane potential, the sodium/potassium ATPase pumps sodium extracellularly, 
while the opposite happens to the potassium ions. The conduction of impulses along nerve 
fibres occurs as small brief, localised spikes of depolarisation on the surface of the cell 
membrane. Impulses travel in one direction as the axonal membrane that has just under‐
gone depolarisation remains in the refractory state until the resting potential is restored 
by the Sodium/Potassium ATPass pumps on [2]. Figure 3 illustrates the sequence of events 
occurring during the propagation of the action potential.
1.4. Pharmacology of local anaesthetics
1.4.1. Structure-activity relationship of local anaesthetics
Local anaesthetics consist of a hydrophilic amine and a lipophilic aromatic ring connected by 
an intermediate chain. The structural bond in the intermediate chain determines whether the 
local anaesthetic will be classified as an ester or an amide. Furthermore, the bond in the inter‐
mediate chain determines the pathway of metabolism of the compound. Ester local anaesthet‐
ics are metabolised by plasma pseudocholinesterases, whereas the amides are metabolised in 
the liver by the cytochrome family of enzymes.
Figure 4 illustrates the structure of an ester and amide local anaesthetic showing clearly the 
bonds in the intermediate chains.
Figure 3. Sequence of events occurring during the propagation of the action potential. Source: http://www.vce.bioninja.
com.au/aos‐2‐detecting‐and‐respond/coordination‐‐regulation/nervous‐system.html. Used with permission 05/11/2016.
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1.4.2. Mechanism of action of local anaesthetics
Local anaesthetic blocks the transmission of nerve impulses by reversibly blocking the fast volt‐
age‐gated sodium channels, thereby inducing analgesia and anaesthesia. Physicochemically, 
local anaesthetics are weak bases that are formulated in an acidic milieu, hence containing a 
larger proportion of the drug in the ionised state. However, it is the unionised fraction that is 
able to cross the lipid bilayer neuronal membrane and block the voltage‐gated sodium channels 
from the inside of the axoplasm. This blockade renders the sodium channel inactive, and hence, 
no further conduction of impulses occurs. Diagramatically this is well demonstrated by Figure 5.
Figure 4. The structure of an ester and amide local anaesthetic showing clearly the bonds in the intermediate chains. 
Source: Student's Manual, Department of Anaesthesia and Perioperative Medicine. University of Cape Town, South 
Africa. Used with permission, 16/11/2016.
Figure 5. Mechanism of action of local anaesthetics. Source: http://www.esciencecentral.org/ebooks/minimally‐invasive/
anesthesia‐cosmetic‐procedures.php. Used with permission 05/11/2016.
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1.4.3. Determinants of physiological activities of local anaesthetics
The activity of local anaesthetics is influenced by a number of factors. These include the pH of 
the surrounding tissue, the lipid solubility of the local anaesthetic, pKa, the bond in the interme‐
diate chain and its length and the protein binding of the particular local anaesthetic in question. 
Details of how each of these factors influence the activity of local anaesthetics is discussed below:
1. pKa: The pKa is the pH at which the number of ionised and unionised fractions of the 
drug is in equilibrium. The lower the pKa, the more the unionised fraction is present for 
any given pH and hence the faster the onset of action.
2. pH: The lower the pH, that is, acidic milieu, the less the potency because in acidic conditions 
the ionised fraction predominates, there is less of the unionised fraction, and there is 
less of the local anaesthetic available to cross the lipid bilayer and block the voltage‐
gated sodium channels. This explains why local anaesthetic does not have much effi‐
cacy in reducing pain in infected tissues like abscesses in which the pH of such tissues 
is much lower than the physiological pH of 7.4.
3. Lipid solubility: The more lipid soluble the local anaesthetic is, the higher the potency, 
the faster the onset of action and the longer the duration of action. This is because there 
are more drug molecules able to cross the lipid bilayer of the neuronal membrane and 
create a ‘depot’ of the drug from within the axoplasm.
4. Intermediate chain: The longer the intermediate chain, the more potent the local an‐
aesthetic. Bupivacaine has a longer intermediate chain compared to lidocaine. Bupiv‐
acaine is three to four times more potent than lidocaine.
5. Protein binding: Local anaesthetics with higher degrees of protein binding have long‐
er duration of action.
Depending on the type of nerves and their fibres, the sequence of blockade of the nerve fibres 
is illustrated in Table 1.
Fibre type Myelin Diameter  
(μm)
Function Conduction  
velocity
Onset of  
block
A‐α Yes 12–20 Somatic motor and proprioception Fast Slow
A‐β Yes 5–12 Light touch and pressure
A‐γ Yes 3–6 Muscle spindle (stretch)
A‐δ Yes 1–4 Firm touch, pain (fast‐localising) and  
temperature
B Yes 1–3 Preganglionic autonomic
C No 0.3–1.3 Pain (nonlocalising ache),  
temperature, touch, postganglionic autonomic
Slow Fast
Table 1. Classification of nerve fibres and sequence of blockade.
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1.5. Specific local anaesthetics
As discussed above, local anaesthetics are classified as ester and amides. Amethocaine also 
known as tetracaine and cocaine is the ester of clinical importance.
Cocaine was first introduced into clinical practice in 1884. It was first used in ophthalmic surgery 
and later in dental surgery. Currently, it is mainly used topically in ear, nose and throat (ENT) 
surgeries at a concentration of 4–10%. The onset of action is fast and lasts 20–30 min. Due to its 
ability to sensitise adrenergic receptors, it is relatively contraindicated in patients known with 
hypertension and ischaemic heart diseases. Concurrent use of adrenaline is contraindicated 
because cocaine is a potent vasoconstrictor.
Amethocaine (tetracaine) is another ester used widely in clinical practice. It was introduced in 
1930 for ophthalmics/ophthalmology and as a cream for use to locally anaesthetise venepunc‐
ture sites, especially in the paediatric population. The onset of action is relatively fast with a 
long duration of action. A maximum dose of 1 mg/kg is recommended. It is the least metabo‐
lised of ester local anaesthetics and hence possesses a higher risk of toxicity. Other ester local 
anaesthetics in use include benzocaine, prilocaine and 2‐chloroprocaine.
Some of the amide local anaesthetics exhibit isomerism. Previously, sold drugs were racemic 
mixtures containing both the levo and dextro enantiomers. The levorotatory enantiomers of 
local anaesthetics are typically less neural and cardiotoxic than dextrorotatory enantiomers. 
For this reason, most clinicians had a preference/opted for pure enantiomers. With the intro‐
duction of better monitoring and ultrasound‐guided blocks, the racemic mixtures are making 
their way back into clinical practice as they tend to have a longer duration of action [3].
Lidocaine was the first amid local anaesthetics to be introduced in 1948. It remains one of the 
most widely used anaesthetics as it can be used intravenously, intrathecally and as a local 
infiltration. It is also a Class 1b antiarrhythmic drug. It has a fast onset of action due to its pKa 
of 7.8, which is closer to the physiological pH of 7.4, and is moderately water and lipid solu‐
ble. It has a moderate duration of action and is the least toxic of all amides probably due to its 
relatively low protein‐binding capacity of 64%. The addition of adrenaline, a vasoconstrictor, 
reduces its toxicity allowing for higher doses to be used for local tissue infiltrations. The rec‐
ommended doses are 3 mg/kg without adrenaline and 7 mg/kg with adrenaline, respectively. 
Concerns have been raised over neurotoxicity with lidocaine making it much less popular 
in recent years for intrathecal usage. For localised procedures such as hand surgeries, 0.5% 
lidocaine intravenously post‐exsanguination of the limb is still a widely used technique intro‐
duced by August Biers in 1908.
Mepivacaine is an intermediate duration of action compared to lidocaine and bupivacaine. It 
was introduced in 1957. It has a pK
a
 of 7.6. It has similar pharmacokinetic and dynamic proper‐
ties with lidocaine except for some concerns of it being neurotoxic in the neonate. However, its 
properties of low rates of systemic toxicity, rapid onset and dense motor block make mepivacaine 
attractive for procedures such as shoulder surgery.
Ropivacaine was introduced in 1976. It has a pK
a
 of 8.2. Its chemical structure is similar to both 
mepivacaine and bupivacaine. Ropivacaine is available as a pure levorotatory stereoisomer 
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only. It is a pure enantiomer and less cardiotoxic compared with racemic mixtures of other 
local anaesthetics. With respect to its better safety profile, ropivacaine has become a preferred 
long‐acting local anaesthetic for peripheral nerve block anaesthesia for many providers. The 
motor block sparing properties associated with ropivacaine spinal and epidural analgesia 
may provide an advantage over bupivacaine. Despite its safety profile, all standard precau‐
tions pertaining to use of local anaesthetics are encouraged as they have been incidences of 
cardiovascular collapse reported with its use [4].
Bupivacaine exists as levo and dextro enantiomer. Its racemic form was introduced in 1963, 
while levobupivacaine was introduced in 1995. It has a pK
a
 of 8.1 and a protein binding of 
96%. The higher degree of protein binding makes bupivacaine the longest acting and most 
cardiotoxic local anaesthetic if inadvertently administered intravenously. It has been used 
successfully over the years since its introduction and has become the yardstick for all other 
long‐acting local anaesthetics. Interestingly, at low concentration, bupivacaine has the pro‐
pensity for sensory blocks while mildly sparing the motor blocks (differential sensitivity). 
This property allows for ‘walking epidural’ in labour analgesia. The maximum recommended 
dose is 2 mg/kg with or without adrenaline as there is only a modest increase in the duration 
of action when combined with a vasoconstrictor. It is three to four times more potent than 
lidocaine, but the onset of action is much slower.
2. Local anaesthetic toxicity: what factors affect the presentation of 
toxicity and management of toxicity
Local anaesthetic toxicity can be observed at local tissue level and systemically. The systemic 
toxicity of local anaesthetic depends on plasma concentration which in itself is closely related 
to the dose and the site of injection. We, the authors, will first discuss local tissue toxicity and 
thereafter expand on the clinical manifestation of the systemic toxicity.
2.1. Local tissue toxicity
2.1.1. Local anaesthetic-induced neurotoxicity
Local anaesthetics exert a direct time and dose‐dependant toxicity on neurons and myocytes. The 
mere injection of local anaesthetics perineurally or intrathecally is a risk factor for perioperative 
nerve injury. Local anaesthetic‐induced nerve injury may occur at clinical concentration levels 
when accidentally injected intrafascicularly. In an experimental model, axonal degeneration has 
been noticed in such instances [5].
Some local anaesthetics are packaged in concentration much higher than used in clinical 
practice. Care should be taken to prepare a safe dilution to reduce the risk of nerve toxic‐
ity. The outer layer of connective tissue surrounding the nerve fibre, the perineurium, forms 
the ‘blood‐nerve barrier’ and protects the nerve from chemical injury. The correct dilution of 
local anaesthetics will ensure that the concentration in the perineural and intraneural milieu is 
within the therapeutic range, thereby avoiding neural damage. The use of adjuncts to increase 
the viscosity of the solution also has been associated with increased incidence of nerve injury. 
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The use of hyperbaric solution in continuous spinal anaesthesia cases leads to the pooling of 
the solution in the caudal dural sac and prolongs the toxic effect on the nerve fibres (i.e. cauda 
equina syndrome) [6]. Transient neurologic syndrome after a single bolus of lignocaine for 
spinal anaesthesia has been reported as well, though with a good outcome in the short term [7]. 
Lignocaine seems more prone to cause local anaesthetic neurotoxicity than bupivacaine with 
risk of 6.5 as high as bupivacaine probably due to the former's lower pKa, and hence, more 
unionised drug crosses into the axoplasm [8].
2.1.2. Incidence and risk factors
The true incidence of local anaesthetic‐induced neurotoxicity is difficult to account for as 
there are many confounding risk factors in the perioperative period that can lead to nerve 
injury. Large prospective studies have shown that the overall incidence of neurologic compli‐
cation with peripheral nerve block technique is <3%. Most of these complications are transient 
sensory deficits [9, 10]. The risk factors pertaining to neurotoxicity will further be grouped as 
anaesthetic factors, surgical factors and patient factors.
1. Anaesthetic factors
(a) Peripheral nerve blocking is an independent risk factor for local anaesthetic neuro‐
toxicity [11].
(b) The site of injection of local anaesthetics. More claims of neurotoxicity have been tabled after 
brachial plexus block than other blocks, after intrafascicular than extrafascicular injection as 
the earlier directly exposes the nerve fibre to high concentration of local anaesthetics [12, 13].
2. Surgical risk factors
The use of tourniquet to reduce blood loss and provide favourable operative field 
causes compression of nerve fibre and tissue ischaemia which has synergetic effect 
as far as local anaesthetic neurotoxicity is concerned. Furthermore, the vasa nervo‐
rum is compressed by tourniquet use, and the washout of local anaesthetic is reduced, 
thereby prolonging the exposure of nerve fibre to local anaesthesia.
3. Patient risk factors
(a) Pre‐existing neuropathies: diabetic peripheral neuropathy, Guillain‐Barre syndrome and 
multiple sclerosis all put the nerve fibre at increased risk of local anaesthetic‐induced 
neurotoxicity.
(b) Peripheral vascular diseases: vasculitis, smoking and hypertension affect the microvascu‐
lature and therefore may make nerves more vulnerable to ischaemia and increased risk of 
neurotoxicity of local anaesthetics during the perioperative period.
2.1.3. Pathophysiology
The mechanism of this neurotoxicity at a cellular level is not well elucidated. The postulated 
mechanisms involve the intrinsic caspase pathway, the phosphoinositide 3‐kinase (PI3K) 
pathway and the mitogen‐activated protein kinase (MAPK) pathway, but there is no consen‐
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sus on what the predominant pathway may be [14, 15]. The interaction of the local anaesthetic 
and the voltage‐gated sodium channel (VGSC) and G‐coupled protein receptors is unlikely 
to be the pathophysiological pathway through which local anaesthetics exert their neuro‐
toxicity. A study using tetrodotoxin, another sodium channel blocker, does not support that 
hypothesis [16].
2.1.4. Local anaesthetic-induced muscle toxicity
Local anaesthetics cause muscle damage after intramuscular injection. The effect is more pro‐
nounced with potent and long‐acting local anaesthetic like bupivacaine. These effects on skeletal 
muscle are transient and with full recovery within 2 weeks.
The tissue toxicity may also be the result of preservative used to maintain stability of drug 
molecules in solution. Sodium bisulphite and ethylene glycol tetra acetic acid are thought to 
be the culprits for the neurotoxicity of chloroprocaine.
2.2. Systemic toxicity
Systemic toxicity from local anaesthetics is closely related to the systemic concentration 
achieved either through excessive dose or inadvertent intravascular injection of local anaes‐
thetics. The cardiovascular system and central nervous system are the most affected systems, 
the latter being more sensitive than the former. This entails that the local anaesthetic blood 
concentration required to produce the toxic sign and symptoms is lower for the CNS than for 
the cardiovascular system (CVS). This translates in clinical practice as the appearance of signs 
and symptoms of CNS toxicity first, followed by those of the CVS. However, caution needs 
to be exercised here as when a patient is having a conscious sedation or a full general anaes‐
thetic, the CNS toxicity may be masked and the cardiotoxicity in the form of cardiovascular 
collapse may be the only manifestation of the local anaesthetic toxicity. The main risk factors 
for developing systemic toxicity are:
• extremes of age (younger than 4 months or older than 79 years)
• pre‐existing heart conduction abnormality




• injection at a highly vascular site (e.g. intercostal block).
2.2.1. Central nervous system toxicity
The signs and symptoms of central nervous system toxicity are generally classified into two 
distinct phases, the excitatory phase and the depression phase, respectively.
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2.2.1.1. The excitatory phase
The earliest symptom is usually the metallic taste, followed by circumoral numbness, light‐
headedness, dizziness, visual disturbances, disorientation, tinnitus and agitation. During this 
period, signs of toxicity include shivering, muscular twitching, tremor and generalised tonic‐
clonic convulsion. The generally accepted explanation for this sequence of events is that the 
inhibitory neurons are the first to be blocked by local anaesthetics leaving the activity of the 
excitatory neurons unopposed [17].
2.2.1.2. The depression phase
The muscle twitches and convulsion subsides, followed by respiratory depression and respira‐
tory arrest. The respiratory depression will lead to hypoventilation and raised plasma pCO
2
 and 
a state of respiratory acidosis which will potentiate the CNS toxicity of local anaesthetics [18]. 
The explanation for this increased CNS toxicity relies on the fact that raised plasma CO
2
 level 
increases its diffusion into the cell, therefore decreasing the intracellular pH. The acidic intra‐
cellular environment will favour the conversion of the unionised local anaesthetics to the 
ionised form, which will be unable to diffuse out of the cell leading to a phenomenon known 
as ion trapping. Decreased plasma binding of local anaesthetics [19] and increased cerebral 
blood flow contribute to the increased delivery of local anaesthetics to the brain, and this too 
increases the likelihood of CNS toxicity.
The clinician needs to be aware of these facts as they will influence the approach to manage‐
ment of the CNS toxicity of local anaesthetics.
2.2.2. Cardiovascular system toxicity
The effect of local anaesthetics on the cardiovascular system is direct and indirect. They 
affect the heart directly through the decrease in the rate of depolarisation of conducting 
cell and cardiomyocytes secondary to the block of voltage‐gated sodium channel. There is 
a decrease in the duration of action potential and refractory period [20, 21]. Various local 
anaesthetics have a different degree of disruption of the conduction of action potential 
through the heart. Bupivacaine depresses the conduction to a greater degree than ligno‐
caine. It produces cardiovascular toxicity at a lower concentration than that of lignocaine 
and has a worse outcome after cardiac resuscitation. However, ropivacaine and levobupi‐
vacaine, a pure S‐enantiomer of bupivacaine, do not share this tendency for greater cardiac 
toxicity [22].
A raised plasma level of local anaesthetics first prolongs the duration of conduction in the 
atrium and ventricle noticed on an electrocardiogram as PR interval prolongation and QRS 
complex widening. The spontaneous pacemaker activity is depressed at a higher plasma level 
resulting in bradycardia and sinus arrest successively. Ventricular arrhythmia occurs more 
often with bupivacaine than lignocaine, with an increased risk in pregnant patients. Apart 
from conduction disturbance, local anaesthetics also have a negative inotropic  activity [23] on 
the heart through interference with sarcolemmal sodium and calcium channel activities [24].
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Low concentration of local anaesthetics causes vasoconstriction, and higher concentration 
causes vasodilation with the exception of cocaine, which consistently produces vasoconstric‐
tion regardless of the concentration [21].
2.2.3. Management of local anaesthetic toxicity
The management of cardiovascular toxicity is based on sound understanding and imple‐
mentation of the basic principle of cardiopulmonary resuscitation [25]. The steps for effective 
management of CNS toxicity of local anaesthetics include:
• Stop injection or infusion of the agent.
• Call for help and start basic life support.
• Airway management: administer 100% O
2
 to prevent hypoxaemia, ventilate the patient to 
prevent hypercarbia, and acidosis which potentiate the CNS toxicity of local anaesthetics [20]. 
Ensure the patency of airway: if the patency of the airway is compromised or patient is un‐
able to maintain the airway, securing the airway endotracheal tube and subsequent ventila‐
tion is recommended.
• Suppress seizures with the use of benzodiazepines or induction of a full general anaesthesia.
• In case of a cardiovascular collapse, effective chest compression as per the advanced car‐
diac life support (ACLS) guideline should commence. Clinicians need to be aware that CPR 
in a setting of local anaesthetics cardiac toxicity will require prolonged effort and dosage 
adjustment (limit epinephrine bolus doses to <1 mcg/kg which is far less than in a classic 
CPR protocol).
• Avoid vasopressin, calcium channel blockers, beta blockers or local anaesthetic in the man‐
agement of cardiac arrhythmia.
• Twenty per cent of intralipid should be used without delay along with the initial resuscita‐
tive measures as per the practice guidelines of the American Society of Regional Anaesthe‐
sia (ASRA) [25].
• A bolus of 1.5 mL/kg IV for 1 min followed by an infusion of 0.25 mL/kg/min.
• Repeat bolus once or twice for persistent cardiovascular collapse.
• Double the infusion rate to 0.5 mL/kg/min if blood pressure remains low.
• Continue infusion for at least 10 min after attaining circulatory stability.
• Recommended upper limit: approximately 10 mL/kg lipid emulsion over the first 30 min.
2.3. Methaemoglobinemia
This is a complication associated with a specific local anaesthetic, namely prilocaine. Prilocaine 
is metabolised in the liver, and o‐toluidine is produced as a by‐product of this metabolism.
O‐toluidine is a strong oxidant that oxidises haemoglobin to methaemoglobin. Severe meth‐
aemoglobinemia can be treated effectively with an infusion of methylene blue [21].
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3. Commonly used Adjuvants to local anaesthetics in clinical practice
Local anaesthetics added to the number of anaesthetic techniques to accommodate various 
patient groups depending on the type of surgery and patient’s functional status. Amide local 
anaesthetics (LA) are the most widely used in modern clinical anaesthetic practice. However, 
Anaesthesiologists still awaits development of an ideal LA with longer duration of action, bet‐
ter nerve fibre selectivity, a lesser degree of motor blockade and lower incidences of systemic 
toxicity. In this quest, multiple adjuvants have been used in clinical practice with varying 
results. This section aims to discuss the adjuvants to LA for nerve blocks, spinal anaesthesia, 
caudals and epidural anaesthesia. The actual techniques and complications are beyond the 
scope of this chapter.
3.1. Adjuvants to local anaesthetics (LA)
1. Opioids
The use of neuraxial opioids in human subjects dates back to 1979 [26, 27]. Since then, they 
have been proven to provide effective and prolonged analgesia [28]. In addition, this synergy 
allows for decreased LA doses with the hope to reduce the incidence of hypotension for simi‐
lar pain relief. Combining LA with intrathecal morphine has been shown to prolong analgesic 
effect after lower limb arthroplasty and spinal anaesthesia [29–31]. Epidural opioids also pro‐
vide similar analgesic benefit although only limited to 6 h following joint arthroplasty [32]. 
These benefits have to be balanced against a high incidence of side effects including respira‐
tory depression (which may be delayed up to several hours post‐administration), nausea, 
vomiting and urinary retention [33]. The evidence for analgesic benefit of using opioids in 
brachial plexus blocks over systemic administration is scanty [34].
Fentanyl has a more rapid onset and shorter duration of action in comparison with more 
hydrophilic opioids such as morphine when administered neuraxially. The recommended 
intrathecal dose is 10–25 μg, and the epidural loading dose is 50–100 μg. It does not prolong 
motor block thus allowing for early ambulation. The duration of action is 2–4 h, and the risk 
of respiratory depression is very low and of short duration.
Morphine: a hydrophilic drug less readily absorbed in the spinal cord resulting in slower 
onset but prolonged duration of analgesia, and as it moves cephalad via CSF, the analgesia 
spreads over more dermatomes. However, this late cephalad spread increases the potential 
for brainstem binding and delayed respiratory depression although very rare in clinical prac‐
tice. The recommended dose is 50–300 μg intrathecal and 2–5 mg epidural loading dose. The 
risk of side effects increases exponentially with the increase in the dose.
Diamorphine: a diacetylated analogue of morphine with a potency of approximately 1.5–2 
times that of morphine resulting in a faster onset and slightly shorter duration of action. The 
intrathecal dose is 300–400 μg, and epidural loading dose is 2–3 mg.
Sufentanil: an intrathecal dose is 2.5–10 μg, and epidural loading dose is 10–50 μg. It is an 
extremely potent opioid with a faster onset of action. Its use in clinical practice is limited by 
its short duration of action and high side effect profile.
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2. Alpha‐2 adrenoceptor agonists
Clonidine: intrathecal use of clonidine as an adjunct to local anaesthetics prolongs the dura‐
tion of sensory blockade by approximately 1 h [35]. However, the duration of motor block‐
ade is increased, and the incidence of hypotension is also high. The recommended dose for 
intrathecal use is in the range of 15–150 μg with the incidence of adverse effects (bradycardia, 
sedation, hypotension) increasing with doses above 150 μg. In paediatric anaesthesia, the use 
of clonidine (1 mg/kg) for caudal blocks doubles the duration of analgesia when compared 
to LA alone, but causes sedation. Further research is needed to examine the benefits of using 
clonidine for peripheral nerve and plexus blocks [36].
Dexmedetomidine is a highly selective alpha‐2 adrenoceptor agonist. There is some evidence 
to suggest a clinical benefit to use of dexmedetomidine with LA for intravenous regional 
anaesthesia [37].
Adrenaline has direct and indirect actions as an adjuvant. It acts directly on α‐2 adrenocep‐
tors in the substantia gelatinosa of the dorsal horn of the spinal cord resulting in presynaptic 
inhibition of transmitter release from C and Aδ fibres. Indirectly, it causes local vasculature 
constriction thus prolonging the duration of action of the LA. Adrenaline used as an adjunct 
to thoracic epidural infusions improves the quality of analgesia [38, 39]. There are conflicting 
reports regarding the use of adrenaline in lumbar epidurals.
3. N‐methyl‐d‐aspartate receptor antagonists
Ketamine: preservative‐free ketamine injected into the caudal epidural space for children at a 
dose of 0.5 mg/kg has been shown to extend analgesia time by several hours. The opponents 
of ketamine cite increased the risk of psychotomimetic side effects, but the use of benzodiaz‐
epine premedication prior to block reduces the risk of these side effects.
Magnesium: intrathecal or epidural magnesium has been used with variable results. It may 
prolong LA/opioid block in women in labour at a dose of 50 mg, but a very high dose of mag‐
nesium has been reported to produce transient neurological toxicity.
4. Other adjuvants
Other adjuvants like midazolam and neostigmine have been suggested to improve the quality 
of analgesia. However, the high incidence of significant side effects far outweighs the small 
improvement in analgesia.
4. Commonly used recipes in clinical practice
1. Spinal anaesthesia (SA) for caesarean delivery
The ideal subarachnoid dose of local anaesthesia for caesarean delivery has been debated for a 
long time. Most anaesthetists employ hyperbaric 0.5% bupivacaine in a dose of 7.5–15.0 mg. A 
meta‐analysis suggests any reduction in the bupivacaine dose during single‐shot SA to less than 
8 mg with opioid or 10 mg alone, resulting in a significantly increased requirement for analgesic 
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supplementation and possibly conversion to general anaesthesia [40]. The practice at our insti‐
tution is to use 10 mg of hyperbaric bupivacaine plus 10 μg fentanyl with satisfactory results.
2. Labour epidural analgesia
The current policy at our institution is to draw up a mixture of 5 mL of 0.5% bupivacaine, 4 mL 
saline and 50 μg fentanyl, that is, a total of 10 mL of 0.25% bupivacaine with 5 μg/mL fentanyl, 
and to administer two 4 mL boluses of this mixture 3 min apart, with the patient in the left lateral 
position for the first bolus and the right lateral for the second. In early labour, an initial bolus of 
8 mL of 0.125% bupivacaine may be given, followed by a repeat dose of a similar volume. The 
aim is to obtain levels of T8–T10 bilaterally, and this can take up to 20 min. Analgesia is main‐
tained with an infusion of 0.125% bupivacaine plus 2 μg/mL fentanyl at the rate of 8–14 mL/h.
Top‐up of labour epidural for caesarean delivery step‐by‐step
• Draw up 17 mL 2% lignocaine, plus 50 μg fentanyl, 1 mL 8.4% sodium bicarbonate and 
1 mL 1/10,000 adrenaline (i.e. 1 mL of an ampoule which has been diluted 10 times). This 
makes a total of 20 mL, with approximately 1/200,000 adrenaline.
• Administer 5 mL boluses after a test dose.
• Unless the initial dose of epidural bupivacaine has been administered within the previous 
hour, treat as though the patient has no block at all. Most patients will require between 16 
and 22 mL for an effective block to T4.
• Conversion to spinal anaesthesia may result in a high block if there has been an unsuccess‐
ful attempt at a top‐up with a large volume of local anaesthetic.
• A poorly functioning epidural catheter is best re‐sited, or spinal anaesthesia may be per‐
formed using a reduced dose (unpredictable), or general anaesthesia may be preferred.
3. Local anaesthetics for regional intravenous anaesthesia
Regional intravenous anaesthesia is indicated for short operative procedures for extremities 
and sometimes for pain therapy (e.g. treatment of complex regional pain syndromes). This is 
a very basic technique, and it requires 12–15 mL of 2% lidocaine or 30–40 mL of 0.5% lidocaine 
for upper extremity regional anaesthesia. Other local anaesthetics such as bupivacaine are 
contraindicated for IV injection for reasons discussed in the toxicity section. Some evidence 
exits supporting a better quality of the block by use if additives such as ketamine and alpha‐2 




• Double pneumatic tourniquet
• Esmarch bandage
• Syringes




• An IV cannula is inserted in the extremity opposite the block side.
• A double pneumatic tourniquet is placed with proximal cuff high on the upper arm.
• A peripheral IV cannula is placed on the limbs on which surgery is to be done as distal as 
feasible
• The block arm is elevated for 1–2 min to allow passive exsanguination, and then, Esmarch 
bandage is wrapped around the arm to exsanguinate the extremity completely.
• The distal cuff is inflated to 50–100 mmHg above systolic BP after which the proximal cuff 
is inflated followed by deflation the distal cuff.
• Inject preservative‐free local anaesthetic (recommended maximum dose is 3 mg/kg).
• After injection IV cannula is removed from anaesthetised hand and pressure is quickly ap‐
plied to puncture site.
• Anaesthesia onset is almost immediate.
• When the patient reports tourniquet pain inflate the distal cuff and deflate the proximal 
cuff.
4. Local anaesthetics for peripheral nerve blocks
There are a wide variety of local anaesthetic agents available for peripheral nerve blocks. 
Important points to consider when making the choice are onset and duration of action, dura‐
tion of the surgical procedure and anticipated degree of pain. Caution is to be used if one 
decided to use additives to local anaesthetics for peripheral nerve blocks to prolong their effect 
as none of the additives discussed in this chapter have got the Food and Drug Administration 
(FDA) approval for this purpose [43].
5. Topical anaesthetics
Topical anaesthetics are used for procedures such as vein cannulation, laceration repair to 
avoid infiltrative local anaesthesia injections and associated pain. They are widely used in 
the paediatric population. There are many dosage forms in clinical use, for example, gels, 
sprays, creams, ointments, patches. Skin absorption is variable and accounts for the systemic 
toxicity. This complication is rare provided the skin is intact with the exception of 5% EMLA 
cream, a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine. Commonly available forms 
are Ametop (4% tetracaine) and EMLA, and more recently, a 4% lidocaine topical cream has 
been introduced. It is better tolerated on the skin while having flexible application times. 
Onset of action for Ametop is between 30 and 40 min and has a duration of action of about 
4–5 h. EMLA on the other hand has a slower onset of about 60 min with a short duration of 
action of about 2 h. Toxicity is largely related to the age of the patients and possible damage 
in the skin. It is recommended that in those below 3 months, duration of application should 
not be more than 1 h, while for age group between 3 and 12 months maximum duration of 
application does not exceed 4 h [44].
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6. Neuraxial techniques in paediatrics
Caudal anaesthesia is a popular technique to provide analgesia in paediatric patients. The sin‐
gle‐shot technique is often adequate for most urological, lower extremity and lower abdomi‐
nal procedures. An indwelling catheter can extend its use to upper abdomen and thoracic 
procedures and offers the added benefit of continuous post‐operative analgesia. The LA dose 
depends on the operative site that ranges from 0.5 to 2 mL/kg of 0.25% bupivacaine, that is, 
the level of the block is proportional to the dose.
Spinal and epidural anaesthesia are safe and effective ways to provide anaesthesia for infants 
[45]. For spinal anaesthesia, bupivacaine 0.5% at a dose 0.5–1 mg/kg is commonly used with 
the dose decreasing with increasing age.
Local anaesthetics add to the armament that is at the disposal of anaesthetists. Understanding 
of their pharmacology increases the safety with which these drugs can be used. Early recog‐
nition of toxicity is core to avoiding central nervous system and cardiorespiratory collapse.
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